Loading…
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.3B | $147M | $48M | $42M | 16.9% | 27.4% | 1897.7% |
| 2024 | $1.0B | $69M | $2M | $46M | 0.9% | 4.1% | -92.6% |
| 2023 | $978M | $106M | $33M | $-38M | 11.5% | 3.8% | -33.7% |
| 2022 | $942M | $117M | $49M | $-5M | 18.7% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 942.26 | 977.89 | 1,017.68 | 1,296.21 |
| Operating Revenue | - | 942.26 | 977.89 | 1,017.68 | 1,296.21 |
| Cost Of Revenue | - | 656.86 | 679.65 | 704.59 | 896.27 |
| Gross Profit | - | 285.40 | 298.24 | 313.09 | 399.94 |
| Operating Expense | - | 206.41 | 226.39 | 259.78 | 289.48 |
| Selling General And Administration | - | 206.41 | 226.39 | 259.78 | 289.48 |
| Total Expenses | - | 863.28 | 906.04 | 964.36 | 1,185.75 |
| Operating Income | - | 78.99 | 71.85 | 53.32 | 110.46 |
| Total Operating Income As Reported | - | 78.99 | 71.85 | 53.32 | 110.46 |
| EBITDA | - | 117.13 | 106.03 | 69.06 | 146.85 |
| Normalized EBITDA | - | 111.92 | 108.49 | 92.93 | 154.72 |
| EBIT | - | 84.43 | 72.02 | 32.89 | 101.24 |
| Interest Income | - | 0.82 | 3.36 | 4.47 | 2.62 |
| Interest Expense | - | 12.10 | 17.95 | 21.97 | 33.25 |
| Net Interest Income | - | -11.88 | -15.32 | -18.54 | -34.60 |
| Other Income Expense | - | 5.22 | -2.46 | -23.86 | -7.87 |
| Interest Income Non Operating | - | 0.82 | 3.36 | 4.47 | 2.62 |
| Interest Expense Non Operating | - | 12.10 | 17.95 | 21.97 | 33.25 |
| Net Non Operating Interest Income Expense | - | -11.88 | -15.32 | -18.54 | -34.60 |
| Pretax Income | - | 72.33 | 54.07 | 10.92 | 67.99 |
| Tax Provision | - | 23.15 | 21.46 | 8.50 | 19.73 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 1.67 | -0.97 | -5.01 | -2.28 |
| Net Income Continuous Operations | - | 49.18 | 32.61 | 2.42 | 48.26 |
| Net Income From Continuing And Discontinued Operation | - | 49.18 | 32.61 | 2.42 | 48.26 |
| Net Income From Continuing Operation Net Minority Interest | - | 49.18 | 32.61 | 2.42 | 48.26 |
| Net Income | - | 49.18 | 32.61 | 2.42 | 48.26 |
| Net Income Common Stockholders | - | 49.18 | 32.61 | 2.42 | 48.26 |
| Net Income Including Noncontrolling Interests | - | 49.18 | 32.61 | 2.42 | 48.26 |
| Normalized Income | - | 45.63 | 34.09 | 21.27 | 53.85 |
| Diluted NI Availto Com Stockholders | - | 49.18 | 32.61 | 2.42 | 48.26 |
| Basic Average Shares | - | 40.50 | 40.50 | 40.50 | 40.52 |
| Diluted Average Shares | - | 40.50 | 40.50 | 40.52 | 40.68 |
| Reconciled Depreciation | - | 32.70 | 34.01 | 36.18 | 45.60 |
| Reconciled Cost Of Revenue | - | 656.86 | 679.65 | 704.59 | 896.27 |
| Total Unusual Items | - | 5.22 | -2.46 | -23.86 | -7.87 |
| Total Unusual Items Excluding Goodwill | - | 5.22 | -2.46 | -23.86 | -7.87 |
| Gain On Sale Of Security | - | 5.22 | -2.46 | -23.86 | -7.87 |
| Total Other Finance Cost | - | 0.59 | 0.73 | 1.04 | 3.98 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Phibro Animal Health Corporationthis co. | PAHC | $1.3B | 27.77↑ premium | 4.69 | 16.9% | 13.79 |
| TransMedics Group, Inc. | TMDX | $2.5B | 12.96 | 5.21 | 40.2% | 16.82 |
| Acadia Healthcare Company, Inc. | ACHC | $2.3B | -2.10 | 1.19 | -56.6% | -6.55 |
| Prestige Consumer Healthcare Inc. | PBH | $2.2B | 11.31 | 1.14 | 10.1% | 9.47 |
| LeMaitre Vascular, Inc. |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| LMAT |
| $2.1B |
| 37.03 |
| 5.43 |
| 14.7% |
| 25.28 |
| Select Medical Holdings Corporation | SEM | $2.0B | 13.99 | 1.20 | 8.6% | 9.20 |
| Neogen Corporation | NEOG | $2.0B | -1.82 | 0.96 | -52.7% | -2.94 |
| ADMA Biologics, Inc. | ADMA | $1.8B | 12.59 | 3.87 | 30.8% | 9.31 |
| Sarepta Therapeutics, Inc. | SRPT | $1.8B | -2.47 | 1.54 | -62.5% | -3.22 |
| Peer Median | - | 11.95 | 1.37 | 9.3% | 9.26 | |